EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Maresin-1 promotes neuroprotection and modulates metabolic and inflammatory responses in disease-associated cell types in preclinical models of multiple sclerosis

Insha Zahoor, Mohammad Nematullah, Mohammad Ejaz Ahmed, Mena Fatma, Mir Sajad, Kameshwar Ayasolla, Mirela Cerghet, Suresh Palaniyandi, Veronica Ceci, Giulia Carrera, Fabio Buttari, Diego Centonze und 4 weitere

Journal of Biological Chemistry · 2025-03 · 301 (3) · 108226

DOI: 10.1016/j.jbc.2025.108226 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025-03. Verfasst von Insha Zahoor und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Henry Ford Health, Detroit, Michigan, USA. Hauptthemen laut MEDLINE: Docosahexaenoic Acids, Encephalomyelitis, Autoimmune, Experimental, Multiple Sclerosis, Neuroprotection. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIAID NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple sclerosis (MS) is a prevalent inflammatory neurodegenerative disease in young people, causing neurological abnormalities and impairment. To investigate a novel therapeutic agent for MS, we observed the impact of maresin 1 (MaR1) on disease progression in a well-known, relapsing-remitting experimental autoimmune encephalomyelitis mouse model. Treatment with MaR1 accelerated inflammation resolution, reduced neurological impairment, and delayed disease development by reducing immune cell infiltration (CD4+IL-17+ and CD4+IFNγ+) into the central nervous system. Furthermore, MaR1 administration enhanced IL-10 production, primarily in macrophages and CD4+ cells. However, neutralizing IL-10 with an anti-IL-10 antibody eliminated the protective impact by MaR1 in relapsing-remitting experimental autoimmune encephalomyelitis model, implying the significance of IL-10 in MaR1 treatment. Metabolism has been recognized as a critical mediator of effector activity in many types of immune cells. In our investigation, MaR1 administration significantly repaired metabolic dysregulation in CD4+ cells, macrophages, and microglia in EAE mice. Furthermore, MaR1 treatment restored defective efferocytosis in treated macrophages and microglia. MaR1 also preserved myelin in EAE mice and regulated O4+ oligodendrocyte metabolism by reversing metabolic dysregulation via increased mitochondrial activity and decreased glycolysis. Overall, in a preclinical MS animal model, MaR1 therapy has anti-inflammatory and neuroprotective properties. It also induced metabolic reprogramming in disease-associated cell types, increased efferocytosis, and maintained myelination. Moreover, our data on patient-derived peripheral blood mononuclear cells substantiated the protective role of MaR1, expanding the therapeutic spectrum of specialized proresolving lipid mediators. Altogether, these findings suggest the potential of MaR1 as a novel therapeutic agent for MS and other autoimmune diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Docosahexaenoic AcidsEncephalomyelitis, Autoimmune, ExperimentalMultiple SclerosisNeuroprotectionNeuroprotective AgentsAnimalsMiceDisease Models, AnimalFemaleInflammationMacrophagesCD4-Positive T-LymphocytesHumansMice, Inbred C57BLInterleukin-10

Stichwörter der Autor:innen

DHAEAEIL-10MSMaresin1MetabolismSCENITHSPMinflammationresolutiontherapeutics

Substanzen

Docosahexaenoic Acids7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acidInterleukin-10Neuroprotective Agents

Autor:innen und Institutionen

  • Department of Neurology, Henry Ford Health, Detroit, Michigan, USA.
  • Division of Hypertension and Vascular Research, Department of Internal Medicine, Henry Ford Health, Detroit, Michigan, USA; Department of Physiology, Wayne State University, Detroit, Michigan, USA.
  • Institute of Translational Pharmacology, National Research Council, Rome, Italy; Laboratory of Resolution of Neuroinflammation, IRCCS Santa Lucia Foundation, Rome, Italy.
  • Laboratory of Resolution of Neuroinflammation, IRCCS Santa Lucia Foundation, Rome, Italy.
  • Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy; Unit of Neurology, IRCCS Neuromed, Pozzilli (Is), Italy.
  • Oklahoma Medical Research Foundation, Oklahoma, Farmington Hills, Michigan, USA.

Förderung

  • NIDDK NIH HHS
  • NIAID NIH HHS
  • NINDS NIH HHS
  • National Institute of Allergy and Infectious Diseases Division of Intramural Research
  • National Institute of Neurological Disorders and Stroke
  • National Multiple Sclerosis Society
  • Henry Ford Health System

Zitieren

APA

Zahoor, I., Nematullah, M., Ahmed, M. E., Fatma, M., Sajad, M., Ayasolla, K., Cerghet, M., Palaniyandi, S., Ceci, V., Carrera, G., Buttari, F., Centonze, D., Mao-Draayer, Y., Rattan, R., Chiurchiù, V., & Giri, S. (2025). Maresin-1 promotes neuroprotection and modulates metabolic and inflammatory responses in disease-associated cell types in preclinical models of multiple sclerosis. Journal of Biological Chemistry, 301(3), 108226. https://doi.org/10.1016/j.jbc.2025.108226

Vancouver

Zahoor I, Nematullah M, Ahmed ME, Fatma M, Sajad M, Ayasolla K, et al. Maresin-1 promotes neuroprotection and modulates metabolic and inflammatory responses in disease-associated cell types in preclinical models of multiple sclerosis. Journal of Biological Chemistry. 2025;301(3):108226. doi:10.1016/j.jbc.2025.108226

BibTeX
@article{Zahoor2025,
  author = {Zahoor, Insha and Nematullah, Mohammad and Ahmed, Mohammad Ejaz and Fatma, Mena and Sajad, Mir and Ayasolla, Kameshwar and Cerghet, Mirela and Palaniyandi, Suresh and Ceci, Veronica and Carrera, Giulia and Buttari, Fabio and Centonze, Diego and Mao-Draayer, Yang and Rattan, Ramandeep and Chiurchiù, Valerio and Giri, Shailendra},
  title = {Maresin-1 promotes neuroprotection and modulates metabolic and inflammatory responses in disease-associated cell types in preclinical models of multiple sclerosis},
  journal = {Journal of Biological Chemistry},
  year = {2025},
  volume = {301},
  number = {3},
  pages = {108226},
  doi = {10.1016/j.jbc.2025.108226}
}
Kostenlos starten →